Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RARB | P10826 | 1/20 | 0.52 |
| ▸ | RARG | P13631 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19362917 | 0.89 | NPC1 (0.74) | MEN1CYP1A2KMT2ANPC1POLB | |
| SCHEMBL5177528 | 0.84 | SRD5A2 (0.53) | MEN1CYP1A2KMT2ANPC1POLB | |
| SCHEMBL3435838 | 0.83 | EPHX2 (0.49) | MEN1CYP1A2KMT2ANPC1POLB | |
| SCHEMBL1261173 | 0.83 | MEN1 (0.59) | MEN1CYP1A2KMT2ASRD5A2ALDH1A1 | |
| SCHEMBL9653084 | 0.83 | SRD5A2 (0.57) | MEN1CYP1A2KMT2ASRD5A2ALDH1A1 | |
| SCHEMBL9578939 | 0.83 | MEN1 (0.59) | MEN1CYP1A2KMT2ASRD5A2ALDH1A1 | |
| SCHEMBL11697929 | 0.83 | MEN1 (0.59) | MEN1CYP1A2KMT2ASRD5A2ALDH1A1 | |
| SCHEMBL8457176 | 0.83 | RXRA (0.76) | NPC1POLBCYP2C9RAB9ASRD5A2 | |
| SCHEMBL16282574 | 0.82 | NPC1 (0.57) | MEN1CYP1A2KMT2ANPC1POLB | |
| SCHEMBL9483965 | 0.82 | EPHX2 (0.50) | MEN1CYP1A2KMT2ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295457-A1 | SURFACE TREATMENT LIQUID AND SURFACE TREATMENT METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230242467-A1 | HIGH PURITY 4-HYDROXYSTYRENE SOLUTION, METHOD OF PRODUCING THE SAME, AND METHOD OF PRODUCING 4-HYDROXYSTYRENE POLYMER | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230217718-A1 | METHOD FOR PRODUCING LIGHT-EMITTING ELEMENTS | CENTRAL GLASS COMPANY, LIMITED (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230217718-A1 | METHOD FOR PRODUCING LIGHT-EMITTING ELEMENTS | CENTRAL GLASS COMPANY, LIMITED (JP) | 2023-07-06 | — | — | US | disclosed |
| EP-3553147-B1 | SURFACE TREATMENT LIQUID AND SURFACE TREATMENT METHOD | TOKYO OHKA KOGYO CO LTD (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| CN-107075148-B | Cellulose ester film and method for producing same | 柯尼卡美能达株式会社 | 2021-01-08 | — | — | CN | disclosed |
| US-9952361-B2 | IR cut filter, method for manufacturing the same, and solid-state imaging device | FUJIFILM CORPORATION (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9884043-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170190923-A1 | NEAR-INFRARED ABSORPTION COMPOSITION, CURABLE COMPOSITION, CURED FILM, NEAR-INFRARED CUT FILTER, SOLID-STATE IMAGING DEVICE, INFRARED SENSOR, CAMERA MODULE, PROCESSED COLORING AGENT, AND METHOD OF MANUFACTURING PROCESSED COLORING AGENT | FUJIFILM CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-7279539-B2 | Alkali-soluble polymer and polymerizable composition thereof | FUJIFILM CORPORATION (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7199142-B2 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7179582-B2 | Radical polymerizable composition and lithographic printing plate precursor using the same | FUJI PHOTO FILM CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1549640-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003105771-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-0790262-B1 | PROPYLENE-ETHYLENE COPOLYMER COMPOSITIONS AND PROCESS FOR THE PRODUCTION THEREOF | CHISSO CORP (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-6005034-A | POLYMER MELTS OF ETHYLENE-PROPYLENE COPOLYMERS | CHISSO CORPOATION (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0790262-A1 | PROPYLENE-ETHYLENE COPOLYMER COMPOSITIONS AND PROCESS FOR THE PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0104813-A1 | Process of manufacturing diaryl esters of dicarboxylic acids | CELANESE CORPORATION (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | MEN1 4042/4885CYP1A2 4867/4885KMT2A 1091/4885 |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | EDNRA, OXGR1, EDNRB | MEN1 3314/4885CYP1A2 428/4885KMT2A 2891/4885 |
| US-20230242467-A1 | HIGH PURITY 4-HYDROXYSTYRENE SOLUTION, METHOD OF PRODUCING THE SAME, AND METHOD OF PRODUCING 4-HYDROXYSTYRENE POLYMER | HAAO, HPD, IL4 | MEN1 3062/4885CYP1A2 1203/4885KMT2A 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.